Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

VBH

- PMLiVE

Sandoz finally wins FDA approval for Neulasta biosimilar

Follows a three year wait since initial rejection in 2016

Article: Market access in Brazil

All eyes on Spinraza

Research Partnership

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Research Partnership

Infographic: Preparing to launch a new asset and in need of demand assessment research?

Download our pre-launch checklist

Research Partnership

Novartis building

Novartis’ Cosentyx misses the mark in Humira head-to-head

Narrowly missed statistical significance for superiority

- PMLiVE

Bedrock are in the Top 3

Bedrock named No. 3 Young Agency by PMLive

Bedrock Healthcare Communications

- PMLiVE

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

Therapy candidate was licensed in a $1bn-plus deal last year

- PMLiVE

Healthcare’s voice revolution

With the UK’s NHS unveiling a major partnership with Amazon’s Alexa, is pharma in danger of being left behind?

- PMLiVE

Novartis grows in Q3 thanks to stellar performance of key drugs

Cosentyx, Entresto and Zolgensma topped drive sales growth

- PMLiVE

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Head-to-head trial with rival Eylea could boost sales

- PMLiVE

Pfizer pays $250m upfront to Akcea for phase 2 antisense drug

Has potential in cardiovascular and metabolic diseases

- PMLiVE

Novartis’ Cosentyx scores again in phase 3, strengthens approval claim

Scopes approval in non-radiographic axial spondyloarthritis

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links